Antineoplastic Agents, Hormonal/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/mortality; Receptor, ErbB-2/metabolism; Receptors, Estrogen/metabolism; Receptors, Progesterone/metabolism; Vascular Endothelial Growth Factor A/metabolism; Adult; Aged; Aged, 80 and over; Breast Neoplasms/metabolism; Carcinoma, Ductal, Breast/drug therapy; Carcinoma, Ductal, Breast/metabolism; Carcinoma, Ductal, Breast/mortality; Carcinoma, Lobular/drug therapy; Carcinoma, Lobular/metabolism; Carcinoma, Lobular/mortality; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Enzyme-Linked Immunosorbent Assay; Female; Goserelin/therapeutic use; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local/drug therapy; Neoplasm Recurrence, Local/mortality; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tamoxifen/therapeutic use; Treatment Outcome